HAP Endorsed Partner Vizient Teams Up with Civica Rx to Improve Affordability and Availability of Generic Drugs > Hospital Association of Pennsylvania


Login to view your account.

Don't have an account? Click here.


HAP Endorsed Partner Vizient Teams Up with Civica Rx to Improve Affordability and Availability of Generic Drugs

June 18, 2019

One of HAP’s endorsed partners, Vizient, has announced that it will be collaborating with Civica Rx, a not-for-profit, non-stock generic drug company that is committed to stabilizing the supply of essential generic medications in a hospital setting.

The Civica Rx initiative launched during January 2018 with a single goal to ensure that essential generic medications are accessible and affordable to patients, and available as soon as possible. Civica Rx was formed by U.S. health systems concerned about predatory pricing and drug shortages. Its founding partners include philanthropic organizations dedicated to improving health care.

Vizient will provide analytic data to identify purchasing patterns and provider needs, and help Civica Rx anticipate gaps in drug availability and affordability.

The collaboration with Civica Rx is the latest effort by Vizient to improve accessibility and lower costs of pharmaceuticals. Vizient currently uses its analytics and data insights, along with its private label pharmacy program, to serve the needs of its member health care organizations and mitigate the effects of drug shortages and lower rising drug costs. 

Recent reports about inpatient drug costs and trends in hospital drug spending and shortages address the impact on hospital budgets and operations, and patient access to care.

Key findings include:

  • The average total drug spending per hospital patient admission increased 18.5 percent between fiscal years 2015 and 2017
  • More than 90 percent of surveyed hospitals reported having to identify alternative therapies to ease the burden of higher drug prices and drug shortages

HAP supports the American Hospital Association’s work to advance policy solutions that address ever-increasing drug prices. Those solutions include:

  • Stopping brand-name manufacturers’ anticompetitive actions
  • Speeding up generic drug approvals
  • Strengthening manufacturers’ drug shortage disclosure requirements
  • Developing drug shortage plans
  • Motivating drug companies to produce drugs in shortage/address delays
  • Encouraging early drug shortage alerts to lessen the risks to patients

HAP is working with the Pennsylvania Congressional Delegation to convey the hospital community’s perspectives and priorities around rising drug costs and drug shortages.

For additional information about prescription drug affordability, contact Laura Stevens Kent, HAP’s vice president, federal legislative advocacy.

« Close